Harbour Investments’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Harbour Investments’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,750	Closed	-$34.2K	–	3351
2023 Q4	$34.2K	Hold	1,750	–	–	﹤0.01%	1622
2023 Q3	$31.3K	Sell	1,750 -500	-22%	-$9.77K	﹤0.01%	1552
2023 Q2	$46.3K	Hold	2,250	–	–	﹤0.01%	1401
2023 Q1	$46K	Hold	2,250	–	–	﹤0.01%	1393
2022 Q4	$50.4K	Hold	2,250	–	–	﹤0.01%	1292
2022 Q3	$52K	Hold	2,250	–	–	﹤0.01%	1252
2022 Q2	$52K	Buy	+2,250	New	+$53.6K	﹤0.01%	1252

Other funds holding GERM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CHC

City Holding Co Charleston, West Virginia $884M AUM 27.52% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

TAM

Tucker Asset Management Littleton, Colorado $405M AUM 27.41% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Harbour Investments's GERM Position: Q1 2024 in Review

Harbour Investments sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q1 2024, closing a stake of 1,750 shares — an estimated $34.2K sold.

Harbour Investments first reported a position in GERM in Q2 2022 and held it in 7 quarters. The position peaked at $52K in Q3 2022. 11 funds tracked by Wall St. Rank hold GERM as of Q1 2024.

Harbour Investments reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q1 2024 after selling out during the quarter.
Harbour Investments sold 1,750 Amplify Treatments, Testing and Advancements ETF shares in Q1 2024, an estimated $34.2K.
Harbour Investments first reported a position in Amplify Treatments, Testing and Advancements ETF in Q2 2022 and held it in 7 quarters.
Harbour Investments's Amplify Treatments, Testing and Advancements ETF position peaked at $52K in Q3 2022.
11 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q1 2024.

Based on Harbour Investments's 13F filing for Q1 2024, filed 22 Jul 2024.